Civil Plaintiff
$97M Settlement Between Gilead and DOJ Over Kickbacks
Amid an industrywide kickbacks investigation into pharma’s charity contributions, Gilead Sciences has become the latest drugmaker to strike a deal. Though the company says it doesn’t believe it violated any laws, it agreed to pay $97 million to resolve kickbacks allegations.
Gilead inked the settlement with the Department of Justice (DOJ) to resolve claims it used a patient foundation as a “conduit” to cover Medicare patients’ copays for Letairis, a pulmonary arterial hypertension drug that’s now off patent.
Gilead is the latest drugmaker to strike a deal in the yearslong probe, following settlements of various sizes for Sanofi, Pfizer, Astellas, Amgen, Alexion and United Therapeutics, among others.
Read the source article at Pharma News
